SANA: IND and phase I/II trial for diabetes therapy and first-in-human CAR T data expected within 12 months
Two innovative platforms are advancing: a hypoimmune cell therapy for type 1 diabetes, with an IND and phase I/II trial planned by year-end, and an in vivo CAR T platform targeting cancer, with first-in-human data for SG293 expected in the next 12 months. Both programs aim for scalable, transformat…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.